Hepatitis B immunology for clinicians

Clinics in Liver Disease

Volumn 14, Issue 3, 2010, Pages 409-424

  Chang, Kyong Mi ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Adaptive immunity; Costimulation; Hepatitis B; Innate immunity; Pathogenesis; Programmed death 1; Regulatory T cells

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; INTERLEUKIN 10; LAMIVUDINE; TRANSCRIPTION FACTOR FOXP3; HEPATITIS B VACCINE;

ADAPTIVE IMMUNITY; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DISEASE COURSE; HEPATITIS B; HUMAN; IMMUNOLOGICAL TOLERANCE; INNATE IMMUNITY; KUPFFER CELL; NATURAL KILLER CELL; NATURAL KILLER T CELL; NONHUMAN; REGULATORY T LYMPHOCYTE; REVIEW; AFRICA SOUTH OF THE SAHARA; ASIA; CELLULAR IMMUNITY; FEMALE; HEPATITIS B VIRUS; HOST PATHOGEN INTERACTION; IMMUNOLOGY; PREGNANCY; PREVALENCE; PREVENTION AND CONTROL; SEXUALLY TRANSMITTED DISEASES, VIRAL; TRANSMISSION; VACCINATION; VERTICAL TRANSMISSION;

ADAPTIVE IMMUNITY; AFRICA SOUTH OF THE SAHARA; ASIA; DISEASE PROGRESSION; FEMALE; HEPATITIS B; HEPATITIS B VACCINES; HEPATITIS B VIRUS; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, INNATE; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; PREGNANCY; PREVALENCE; SEXUALLY TRANSMITTED DISEASES, VIRAL; VACCINATION;

EID: 77954655889     PISSN: 10893261     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cld.2010.05.012     Document Type: Review

References (82)

1. Sommereyns C., Paul S., Staeheli P., et al. IFN-lambda (IFN-lambda) is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo. PLoS Pathog 2008, 4:e1000017.
2. Carayannopoulos L.N., Yokoyama W.M. Recognition of infected cells by natural killer cells. Curr Opin Immunol 2004, 16:26-33.
3. Kirwan S.E., Burshtyn D.N. Regulation of natural killer cell activity. Curr Opin Immunol 2007, 19:46-54.
4. Long E.O., Burshtyn D.N., Clark W.P., et al. Killer cell inhibitory receptors: diversity, specificity, and function. Immunol Rev 1997, 155:135-144.
5. Piccioli D., Sbrana S., Melandri E., et al. Contact-dependent stimulation and inhibition of dendritic cells by natural killer cells. J Exp Med 2002, 195:335-341.
6. Gerosa F., Gobbi A., Zorzi P., et al. The reciprocal interaction of NK cells with plasmacytoid or myeloid dendritic cells profoundly affects innate resistance functions. J Immunol 2005, 174:727-734.
7. Gerosa F., Baldani-Guerra B., Nisii C., et al. Reciprocal activating interaction between natural killer cells and dendritic cells. J Exp Med 2002, 195:327-333.
8. Moretta A. The dialogue between human natural killer cells and dendritic cells. Curr Opin Immunol 2005, 17:306-311.
9. Pacanowski J., Kahi S., Baillet M., et al. Reduced blood CD123+ (lymphoid) and CD11c+ (myeloid) dendritic cell numbers in primary HIV-1 infection. Blood 2001, 98:3016-3021.
10. Boasso A., Shearer G.M. Chronic innate immune activation as a cause of HIV-1 immunopathogenesis. Clin Immunol 2008, 126:235-242.
11. Desai S., Chaparro A., Liu H., et al. Impaired CCR7 expression on plasmacytoid dendritic cells of HIV-infected children and adolescents with immunologic and virologic failure. J Acquir Immune Defic Syndr 2007, 45:501-507.
12. Chehimi J., Campbell D.E., Azzoni L., et al. Persistent decreases in blood plasmacytoid dendritic cell number and function despite effective highly active antiretroviral therapy and increased blood myeloid dendritic cells in HIV-infected individuals. J Immunol 2002, 168:4796-4801.
13. Tu Z., Bozorgzadeh A., Pierce R.H., et al. TLR-dependent cross talk between human Kupffer cells and NK cells. J Exp Med 2008, 205:233-244.
14. Bouaziz J.D., Yanaba K., Tedder T.F. Regulatory B cells as inhibitors of immune responses and inflammation. Immunol Rev 2008, 224:201-214.
15. Guidotti L.G., Chisari F.V. Immunobiology and pathogenesis of viral hepatitis. Annu Rev Pathol Mech Dis 2006, 1:23-61.
16. Freeman G.J., Long A.J., Iwai Y., et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 2000, 192:1027-1034.
17. Latchman Y., Wood C.R., Chernova T., et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol 2001, 2:261-268.
18. Riley J.L., June C.H. The road to recovery: translating PD-1 biology into clinical benefit. Trends Immunol 2006, 28(2):48-50.
19. Freeman G.J., Wherry E.J., Ahmed R., et al. Reinvigorating exhausted HIV-specific T cells via PD-1-PD-1 ligand blockade. J Exp Med 2006, 203:2223-2227.
20. Shevach E.M. CD4+ CD25+ suppressor T cells: more questions than answers. Nat Rev Immunol 2002, 2:389-400.
21. Sakaguchi S. Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 2004, 22:531-562.
22. Rouse B.T., Suvas S. Regulatory cells and infectious agents: detentes cordiale and contraire. J Immunol 2004, 173:2211-2215.
23. Roncarolo M.G., Gregori S., Battaglia M., et al. Interleukin-10-secreting type 1 regulatory T cells in rodents and humans. Immunol Rev 2006, 212:28-50.
24. Moore K.W., de Waal Malefyt R., Coffman R.L., et al. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 2001, 19:683-765.
25. Vicari A.P., Trinchieri G. Interleukin-10 in viral diseases and cancer: exiting the labyrinth?. Immunol Rev 2004, 202:223-236.
26. Zou W., Borvak J., Wei S., et al. Reciprocal regulation of plasmacytoid dendritic cells and monocytes during viral infection. Eur J Immunol 2001, 31:3833-3839.
27. McKenna K., Beignon A.S., Bhardwaj N. Plasmacytoid dendritic cells: linking innate and adaptive immunity. J Virol 2005, 79:17-27.
28. Brown J.A., Dorfman D.M., Ma F.R., et al. Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production. J Immunol 2003, 170:1257-1266.
29. Brooks D.G., Trifilo M.J., Edelmann K.H., et al. Interleukin-10 determines viral clearance or persistence in vivo. Nat Med 2006, 12:1301-1309.
30. Ejrnaes M., Filippi C.M., Martinic M.M., et al. Resolution of a chronic viral infection after interleukin-10 receptor blockade. J Exp Med 2006, 203:2461-2472.
31. Kakimi K., Guidotti L.G., Koezuka Y., et al. Natural killer T cell activation inhibits hepatitis B virus replication in vivo. J Exp Med 2000, 192:921-930.
32. Kimura K., Kakimi K., Wieland S., et al. Activated intrahepatic antigen-presenting cells inhibit hepatitis B virus replication in the liver of transgenic mice. J Immunol 2002, 169:5188-5195.
33. Wieland S., Thimme R., Purcell R.H., et al. Genomic analysis of the host response to hepatitis B virus infection. Proc Natl Acad Sci U S A 2004, 101:6669-6674.
34. Thimme R., Wieland S., Steiger C., et al. CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. J Virol 2003, 77:68-76.
35. Dunn C., Peppa D., Khanna P., et al. Temporal analysis of early immune responses in patients with acute hepatitis B virus infection. Gastroenterology 2009, 137:1289-1300.
36. Hosel M., Quasdorff M., Wiegmann K., et al. Not interferon, but interleukin-6 controls early gene expression in hepatitis B virus infection. Hepatology 2009, 50:1773-1782.
37. Durantel D., Zoulim F. Innate response to hepatitis B virus infection: observations challenging the concept of a stealth virus. Hepatology 2009, 50:1692-1695.
38. Guy C.S., Mulrooney-Cousins P.M., Churchill N.D., et al. Intrahepatic expression of genes affiliated with innate and adaptive immune responses immediately after invasion and during acute infection with woodchuck hepadnavirus. J Virol 2008, 82:8579-8591.
39. Fisicaro P., Valdatta C., Boni C., et al. Early kinetics of innate and adaptive immune responses during hepatitis B virus infection. Gut 2009, 58:974-982.
40. Dunn C., Brunetto M., Reynolds G., et al. Cytokines induced during chronic hepatitis B virus infection promote a pathway for NK cell-mediated liver damage. J Exp Med 2007, 204:667-680.
41. van der Molen R.G., Sprengers D., Biesta P.J., et al. Favorable effect of adefovir on the number and functionality of myeloid dendritic cells of patients with chronic HBV. Hepatology 2006, 44:907-914.
42. Zhang Z., Zhang H., Chen D., et al. Response to interferon-alpha treatment correlates with recovery of blood plasmacytoid dendritic cells in children with chronic hepatitis B. J Hepatol 2007, 47:751-759.
43. Maini M.K., Boni C., Lee C.K., et al. The role of virus-specific CD8(+) cells in liver damage and viral control during persistent hepatitis B virus infection. J Exp Med 2000, 191:1269-1280.
44. Maini M.K., Boni C., Ogg G.S., et al. Direct ex vivo analysis of hepatitis B virus-specific CD8(+) T cells associated with the control of infection. Gastroenterology 1999, 117:1386-1396.
45. Penna A., Artini M., Cavalli A., et al. Long-lasting memory T cell responses following self-limited acute hepatitis B. J Clin Invest 1996, 98:1185-1194.
46. Sprengers D., van der Molen R.G., Kusters J.G., et al. Analysis of intrahepatic HBV-specific cytotoxic T-cells during and after acute HBV infection in humans. J Hepatol 2006, 45:182-189.
47. Penna A., Chisari F.V., Bertoletti A., et al. Cytotoxic T lymphocytes recognize an HLA-A2-restricted epitope within the hepatitis B virus nucleocapsid antigen. J Exp Med 1991, 174:1565-1570.
48. Rehermann B., Fowler P., Sidney J., et al. The cytotoxic T lymphocyte response to multiple hepatitis B virus polymerase epitopes during and after acute viral hepatitis. J Exp Med 1995, 181:1047-1058.
49. Sitia G., Isogawa M., Iannacone M., et al. MMPs are required for recruitment of antigen-nonspecific mononuclear cells into the liver by CTLs. J Clin Invest 2004, 113:1158-1167.
50. Thung S.N. Histologic findings in recurrent HBV. Liver Transpl 2006, 12:S50-S53.
51. Chisari F.V. Hepatitis B virus transgenic mice: insights into the virus and the disease. Hepatology 1995, 22:1316-1325.
52. Iannacone M., Sitia G., Isogawa M., et al. Platelets mediate cytotoxic T lymphocyte-induced liver damage. Nat Med 2005, 11:1167-1169.
53. Rehermann B. Immune responses in hepatitis B virus infection. Semin Liver Dis 2003, 23:21-38.
54. Rehermann B., Lau D., Hoofnagle J.H., et al. Cytotoxic T lymphocyte responsiveness after resolution of chronic hepatitis B virus infection. J Clin Invest 1996, 97:1655-1665.
55. Vandepapeliere P., Lau G.K., Leroux-Roels G., et al. Therapeutic vaccination of chronic hepatitis B patients with virus suppression by antiviral therapy: a randomized, controlled study of co-administration of HBsAg/AS02 candidate vaccine and lamivudine. Vaccine 2007, 25:8585-8597.
56. Chen M.T., Billaud J.N., Sallberg M., et al. A function of the hepatitis B virus precore protein is to regulate the immune response to the core antigen. Proc Natl Acad Sci U S A 2004, 101:14913-14918.
57. Chen M., Sallberg M., Hughes J., et al. Immune tolerance split between hepatitis B virus precore and core proteins. J Virol 2005, 79:3016-3027.
58. Wherry E.J., Ahmed R. Memory CD8 T-cell differentiation during viral infection. J Virol 2004, 78:5535-5545.
59. Boettler T., Panther E., Bengsch B., et al. Expression of the interleukin-7 receptor alpha chain (CD127) on virus-specific CD8+ T cells identifies functionally and phenotypically defined memory T cells during acute resolving hepatitis B virus infection. J Virol 2006, 80:3532-3540.
60. Boni C., Fisicaro P., Valdatta C., et al. Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection. J Virol 2007, 81:4215-4225.
61. Fisicaro P., Valdatta C., Massari M., et al. Antiviral intrahepatic T-cell responses can be restored by blocking programmed death-1 pathway in chronic hepatitis B. Gastroenterology 2009, 138(2):682-693.
62. Thio C.L., Mosbruger T.L., Kaslow R.A., et al. Cytotoxic T-lymphocyte antigen 4 gene and recovery from hepatitis B virus infection. J Virol 2004, 78:11258-11262.
63. Stoop J.N., van der Molen R.G., Baan C.C., et al. Regulatory T cells contribute to the impaired immune response in patients with chronic hepatitis B virus infection. Hepatology 2005, 41:771-778.
64. Franzese O., Kennedy P.T., Gehring A.J., et al. Modulation of the CD8+-T-cell response by CD4+ CD25+ regulatory T cells in patients with hepatitis B virus infection. J Virol 2005, 79:3322-3328.
65. Xu D., Fu J., Jin L., et al. Circulating and liver resident CD4+CD25+ regulatory T cells actively influence the antiviral immune response and disease progression in patients with hepatitis B. J Immunol 2006, 177:739-747.
66. Fu J., Xu D., Liu Z., et al. Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients. Gastroenterology 2007, 132:2328-2339.
67. Bertoletti A., D'Elios M.M., Boni C., et al. Different cytokine profiles of intraphepatic T cells in chronic hepatitis B and hepatitis C virus infections. Gastroenterology 1997, 112:193-199.
68. Hyodo N., Tajimi M., Ugajin T., et al. Frequencies of interferon-gamma and interleukin-10 secreting cells in peripheral blood mononuclear cells and liver infiltrating lymphocytes in chronic hepatitis B virus infection. Hepatol Res 2003, 27:109-116.
69. Hyodo N., Nakamura I., Imawari M. Hepatitis B core antigen stimulates interleukin-10 secretion by both T cells and monocytes from peripheral blood of patients with chronic hepatitis B virus infection. Clin Exp Immunol 2004, 135:462-466.
70. Bertoletti A., Costanzo A., Chisari F.V., et al. Cytotoxic T lymphocyte response to a wild type hepatitis B virus epitope in patients chronically infected by variant viruses carrying substitutions within the epitope. J Exp Med 1994, 180:933-943.
71. Bertoletti A., Sette A., Chisari F.V., et al. Natural variants of cytotoxic epitopes are T-cell receptor antagonists for antiviral cytotoxic T cells. Nature 1994, 369:407-410.
72. Webster G.J., Reignat S., Brown D., et al. Longitudinal analysis of CD8+ T cells specific for structural and nonstructural hepatitis B virus proteins in patients with chronic hepatitis B: implications for immunotherapy. J Virol 2004, 78:5707-5719.
73. Rehermann B., Pasquinelli C., Mosier S.M., et al. Hepatitis B virus (HBV) sequence variation of cytotoxic T lymphocyte epitopes is not common in patients with chronic HBV infection. J Clin Invest 1995, 96:1527-1534.
74. Mizukoshi E., Sidney J., Livingston B., et al. Cellular immune responses to the hepatitis B virus polymerase. J Immunol 2004, 173:5863-5871.
75. Rehermann B., Ferrari C., Pasquinelli C., et al. The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat Med 1996, 2:1104-1108.
76. Bertoletti A., Maini M., Williams R. Role of hepatitis B virus specific cytotoxic T cells in liver damage and viral control. Antiviral Res 2003, 60:61-66.
77. Gehring A.J., Sun D., Kennedy P.T., et al. The level of viral antigen presented by hepatocytes influences CD8 T-cell function. J Virol 2007, 81:2940-2949.
78. Kaplan D.E., Sugimoto K., Ikeda F., et al. T-cell response relative to genotype and ethnicity during antiviral therapy for chronic hepatitis C. Hepatology 2005, 41:1365-1375.
79. Rahman F., Heller T., Sobao Y., et al. Effects of antiviral therapy on the cellular immune response in acute hepatitis C. Hepatology 2004, 40:87-97.
80. Boni C., Penna A., Ogg G.S., et al. Lamivudine treatment can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitis B: new perspectives for immune therapy. Hepatology 2001, 33:963-971.
81. Boni C., Penna A., Bertoletti A., et al. Transient restoration of anti-viral T cell responses induced by lamivudine therapy in chronic hepatitis B. J Hepatol 2003, 39:595-605.
82. Boni C., Bertoletti A., Penna A., et al. Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B. J Clin Invest 1998, 102:968-975.